Literature DB >> 3036247

Bryostatins mimic the effects of phorbol esters in intact human platelets.

E A Tallant, J B Smith, R W Wallace.   

Abstract

Bryostatin-7 induces aggregation of human platelets and the phosphorylation of specific platelet proteins. Both the rate and extent of aggregation are similar to that induced by the tumor promoter phorbol ester 12-myristate 13-acetate (PMA); however, the rate of response is markedly reduced compared to that induced by thrombin. The addition of bryostatin-7 to 32P-labeled platelets results in a time-dependent incorporation of 32P into proteins of 20, 47 and 250 kDa; proteins of similar molecular mass are phosphorylated in response to the addition of thrombin or PMA. The time courses and dose responses of the phosphorylations induced by bryostatin-7 are similar to those found with PMA. In addition, bryostatin-7 increases the level of 32P incorporation into platelet polyphosphoinositides, which also occurs in response to PMA. These results suggest that, in intact human platelets, bryostatin-7 mimics the phorbol ester tumor promoter by directly activating protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036247     DOI: 10.1016/0167-4889(87)90239-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.

Authors:  Paul M Barr; Hillard M Lazarus; Brenda W Cooper; Mark D Schluchter; Ashok Panneerselvam; James W Jacobberger; Jack W Hsu; Nalini Janakiraman; Aleksandra Simic; Afshin Dowlati; Scot C Remick
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

2.  Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.

Authors:  Noemi Kedei; Nancy E Lewin; Tamás Géczy; Julia Selezneva; Derek C Braun; Jinqiu Chen; Michelle A Herrmann; Madeleine R Heldman; Langston Lim; Poonam Mannan; Susan H Garfield; Yam B Poudel; Thomas J Cummins; Arnab Rudra; Peter M Blumberg; Gary E Keck
Journal:  ACS Chem Biol       Date:  2013-02-01       Impact factor: 5.100

3.  A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

Authors:  J Prendiville; D Crowther; N Thatcher; P J Woll; B W Fox; A McGown; N Testa; P Stern; R McDermott; M Potter
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.